Kronos Bio Competitors

Sarepta Therapeutics (NASDAQ:SRPT) and Kronos Bio (NASDAQ:KRON) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their profitability, valuation, risk, institutional ownership, earnings, analyst recommendations and dividends.

Profitability

This table compares Sarepta Therapeutics and Kronos Bio's net margins, return on equity and return on assets.

Valuation & Earnings

This table compares Sarepta Therapeutics and Kronos Bio's gross revenue, earnings per share (EPS) and valuation.

Kronos Bio has lower revenue, but higher earnings than Sarepta Therapeutics.

Insider and Institutional Ownership

89.7% of Sarepta Therapeutics shares are held by institutional investors. 5.9% of Sarepta Therapeutics shares are held by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Analyst Recommendations

This is a breakdown of recent ratings and recommmendations for Sarepta Therapeutics and Kronos Bio, as provided by MarketBeat.com.

Sarepta Therapeutics presently has a consensus target price of $150.4762, suggesting a potential upside of 116.89%. Kronos Bio has a consensus target price of $43.6667, suggesting a potential upside of 71.85%. Given Sarepta Therapeutics' higher probable upside, research analysts clearly believe Sarepta Therapeutics is more favorable than Kronos Bio.

Summary

Sarepta Therapeutics beats Kronos Bio on 5 of the 9 factors compared between the two stocks.

Allakos (NASDAQ:ALLK) and Kronos Bio (NASDAQ:KRON) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Allakos and Kronos Bio's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Allakos and Kronos Bio's gross revenue, earnings per share and valuation.

Insider and Institutional Ownership

65.4% of Allakos shares are held by institutional investors. 44.8% of Allakos shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Allakos and Kronos Bio, as reported by MarketBeat.com.

Allakos presently has a consensus target price of $181.50, suggesting a potential upside of 73.83%. Kronos Bio has a consensus target price of $43.6667, suggesting a potential upside of 71.85%. Given Allakos' higher probable upside, equities research analysts clearly believe Allakos is more favorable than Kronos Bio.

Summary

Allakos beats Kronos Bio on 3 of the 5 factors compared between the two stocks.

Blueprint Medicines (NASDAQ:BPMC) and Kronos Bio (NASDAQ:KRON) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Blueprint Medicines and Kronos Bio's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Blueprint Medicines and Kronos Bio's gross revenue, earnings per share and valuation.

Kronos Bio has lower revenue, but higher earnings than Blueprint Medicines.

Analyst Ratings

This is a summary of recent recommendations for Blueprint Medicines and Kronos Bio, as reported by MarketBeat.com.

Blueprint Medicines presently has a consensus target price of $111.00, suggesting a potential upside of 19.86%. Kronos Bio has a consensus target price of $43.6667, suggesting a potential upside of 71.85%. Given Kronos Bio's stronger consensus rating and higher probable upside, analysts clearly believe Kronos Bio is more favorable than Blueprint Medicines.

Summary

Blueprint Medicines beats Kronos Bio on 6 of the 8 factors compared between the two stocks.

Perrigo (NYSE:PRGO) and Kronos Bio (NASDAQ:KRON) are both medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their earnings, risk, institutional ownership, dividends, profitability, valuation and analyst recommendations.

Profitability

This table compares Perrigo and Kronos Bio's net margins, return on equity and return on assets.

Valuation and Earnings

This table compares Perrigo and Kronos Bio's gross revenue, earnings per share and valuation.

Perrigo has higher revenue and earnings than Kronos Bio.

Insider and Institutional Ownership

82.7% of Perrigo shares are held by institutional investors. 0.3% of Perrigo shares are held by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Analyst Ratings

This is a summary of recent recommendations for Perrigo and Kronos Bio, as reported by MarketBeat.com.

Perrigo presently has a consensus target price of $52.00, suggesting a potential upside of 28.33%. Kronos Bio has a consensus target price of $43.6667, suggesting a potential upside of 71.85%. Given Kronos Bio's stronger consensus rating and higher probable upside, analysts clearly believe Kronos Bio is more favorable than Perrigo.

Summary

Perrigo beats Kronos Bio on 5 of the 9 factors compared between the two stocks.

Schrödinger (NASDAQ:SDGR) and Kronos Bio (NASDAQ:KRON) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Schrödinger and Kronos Bio's net margins, return on equity and return on assets.

Institutional & Insider Ownership

41.3% of Schrödinger shares are held by institutional investors. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Schrödinger and Kronos Bio's revenue, earnings per share and valuation.

Kronos Bio has lower revenue, but higher earnings than Schrödinger.

Analyst Ratings

This is a summary of current ratings for Schrödinger and Kronos Bio, as reported by MarketBeat.com.

Schrödinger currently has a consensus price target of $85.50, indicating a potential upside of 15.73%. Kronos Bio has a consensus price target of $43.6667, indicating a potential upside of 71.85%. Given Kronos Bio's stronger consensus rating and higher probable upside, analysts clearly believe Kronos Bio is more favorable than Schrödinger.

Summary

Kronos Bio beats Schrödinger on 6 of the 8 factors compared between the two stocks.

Galapagos (NASDAQ:GLPG) and Kronos Bio (NASDAQ:KRON) are both medical companies, but which is the superior business? We will compare the two businesses based on the strength of their analyst recommendations, risk, earnings, institutional ownership, valuation, dividends and profitability.

Profitability

This table compares Galapagos and Kronos Bio's net margins, return on equity and return on assets.

Institutional & Insider Ownership

11.2% of Galapagos shares are held by institutional investors. 2.9% of Galapagos shares are held by insiders. Strong institutional ownership is an indication that large money managers, endowments and hedge funds believe a stock is poised for long-term growth.

Valuation and Earnings

This table compares Galapagos and Kronos Bio's revenue, earnings per share and valuation.

Galapagos has higher revenue and earnings than Kronos Bio.

Analyst Ratings

This is a summary of current ratings for Galapagos and Kronos Bio, as reported by MarketBeat.com.

Galapagos currently has a consensus price target of $143.7273, indicating a potential upside of 85.72%. Kronos Bio has a consensus price target of $43.6667, indicating a potential upside of 71.85%. Given Galapagos' higher probable upside, equities research analysts clearly believe Galapagos is more favorable than Kronos Bio.